| 0.6855 0 (0%) | 04-19 15:58 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.36 | 1-year : | 2.2 |
| Resists | First : | 1.17 | Second : | 1.88 |
| Pivot price | 0.22  |
|||
| Supports | First : | 0.01 | Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.35 |
| MA(100) : | 1.84 |
MA(250) : | 2 |
|
| MACD | MACD : | -0.4  |
Signal : | -0.4 |
| %K %D | K(14,3) : | 1.1 |
D(3) : | 0.6 |
| RSI | RSI(14): 16.6 |
|||
| 52-week | High : | 3.72 | Low : | 0.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LCI ] has closed above bottom band by 29.4%. Bollinger Bands are 5.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania.
Fri, 12 May 2023
Lannett official: Bankruptcy won't affect Seymour facility - Seymour Tribune
Tue, 02 May 2023
LANNETT COMPANY, INC. FILES PREPACKAGED CHAPTER 11 ... - PR Newswire
Thu, 20 Apr 2023
NYSE TO SUSPEND TRADING IMMEDIATELY IN LANNETT ... - PR Newswire
Tue, 04 Apr 2023
LANNETT SHARES UPDATE - PR Newswire
Wed, 01 Feb 2023
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND ... - PR Newswire
Wed, 25 Jan 2023
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 11 (M) |
| Shares Float | 8 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 38.9 (%) |
| Shares Short | 1,240 (K) |
| Shares Short P.Month | 1,050 (K) |
| EPS | -19.14 |
| EPS Est Next Qtrly | 0.66 |
| EPS Est This Year | 2.59 |
| EPS Est Next Year | 2.75 |
| Book Value (p.s.) | -30.29 |
| Profit Margin | -62.5 % |
| Operating Margin | -20.9 % |
| Return on Assets (ttm) | -7.9 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -6.5 % |
| Gross Profit (p.s.) | 4.28 |
| Sales Per Share | 28.64 |
| EBITDA (p.s.) | -3.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | 19 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|